← Back to Search

Procedure

ALPPS for Liver Tumors (ALPPS Trial)

Phase 2
Waitlist Available
Research Sponsored by University of Zurich
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2012-2015
Awards & highlights

Summary

This randomized phase II trial compares how well associating liver partition with portal vein ligation for staged hepatectomy (ALPPS) or portal vein occlusion (PVO) works in treating patients with liver cancer. Both treatments are types of 2-stage hepatectomies for removing liver cancer. ALPPS may be more effective than PVO in patients whose disease would traditionally be considered inoperable. * Trial with surgical intervention

Eligible Conditions
  • Liver Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2012-2015
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2012-2015 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Progression of disease

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: ALPPSExperimental Treatment1 Intervention
Patients undergo Liver partition and portal vein ligation to induce hypertrophy of the future liver remnant
Group II: PVOActive Control1 Intervention
Patient undergo portal vein embolization or ligation

Find a Location

Who is running the clinical trial?

University of ZurichLead Sponsor
1,180 Previous Clinical Trials
1,295,454 Total Patients Enrolled
~1 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top